Alnylam Pharmace. buy UBS Group AG
Start price
28.06.24
/
50%
€228.00
Target price
28.06.25
€268.93
Performance (%)
20.53%
End price
29.06.25
€274.80
Summary
This prediction ended on 29.06.25 with a price of €274.80. The BUY prediction by UBS_Group_AG finished with a performance of 20.53%. UBS_Group_AG has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. UBS_Group_AG has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -6.368% | -6.368% | 25.633% |
| iShares Core DAX® | 1.644% | 4.865% | 25.089% |
| iShares Nasdaq 100 | 0.747% | 2.923% | 8.975% |
| iShares Nikkei 225® | 2.442% | 6.212% | 21.408% |
| iShares S&P 500 | 0.618% | 2.843% | 5.726% |
Comments by UBS_Group_AG for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at UBS Group AG from $253.00 to $288.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten
Current prediction by UBS_Group_AG for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€347.20
01.08.25
01.08.25
€481.91
01.08.26
01.08.26
-8.53%
13.01.26
13.01.26
